ANIX Earnings — Anixa Biosciences, Inc. Post-ER Performance | BigEarnings
ANIX — Anixa Biosciences, Inc.
XNAS · Healthcare · Biotechnology
Price$2.56
Market Cap$85.8M
P/E—
52W Range$2.44 – $5.46
Next Earnings2026-06-16
About Anixa Biosciences, Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
